Global Acute Respiratory Distress Syndrome Market Overview:
According to SPER Market Research, the Global Acute Respiratory Distress Syndrome Market is estimated to reach USD 2.97 billion by 2030 with a CAGR of 10.9%.
Acute respiratory distress syndrome (ARDS) is a potentially fatal lung injury in which fluid leaks into the lungs. Most individuals who develop ARDS are already in the hospital due to trauma or condition such as COVID-19. Fluids build up in the tiny, elastic air sacs called alveoli in the lungs, causing the condition. Because of the fluid buildup, less oxygen reaches the bloodstream. This deprives the organs of enough oxygen for normal function. The causes of ARDS are classified as either direct or indirect lung injuries. Pneumonia, aspiration, trauma, and other direct lung injuries are examples. Inflammation of the pancreas, severe infection (also known as sepsis), blood transfusions, burns, and medication reactions are examples of indirect lung injuries. Shortness of breath, cough, and fever are common ARDS symptoms. Low blood oxygen levels, rapid breathing, and clicking bubbling, or rattling sounds in the lungs when breathing are other signs and symptoms of ARDS. CT scans and other imaging techniques are increasingly being used in the diagnosis and management of ARDS. Another modality that can be used as a bedside tool to aid in the diagnosis of ARDS is lung ultrasound.
The rising prevalence and incidence of acute lung injury, a diverse set of risk factors for ARDS, and a rapid increase in the patient pool of Covid-19 with ARDS are driving the acute respiratory distress syndrome (ARDS) market. Other factors expected to drive the growth of the global acute respiratory distress syndrome (ARDS) market include rising levels of air pollution and lifestyle-related diseases, as well as an increase in accident and trauma-related ARDS. The increasing population and rapidly growing usage of personal transportation, has led to a considerable rise of harmful gases emitted by vehicles hence leading to a rise in levels of air pollution which in turn leads to a rise in ARDS cases. The changing lifestyle gives rise to several other risk factors such as obesity, alcohol abuse, low blood protein, chemotherapy, etc. which along with the increasing public awareness about ARDS and the growing healthcare infrastructure in developing economies; are some of the driving factors of the market growth.
The key factor driving the growth of this market is the availability of appropriate diagnosis and treatment. Pulse oximeters, blood gas analyzers, spirometers and capnography devices are some of the diagnostic devices which help in the early diagnosis of ARDS which further makes proper therapy and treatment available to the patients. Because of the country's increasing technological advancement, the diagnosis segment in the North American region is expected to grow at the fastest rate during the forecast period. Due to an increase in chronic respiratory diseases and widespread adoption of proper diagnosis, Germany's diagnosis segment dominates the European market. Because of the growing number of biotechnology centers and research activities in Japan, the diagnosis segment is dominating the Asia-Pacific market. However, factors such as treatment complications and high device and treatment costs are impeding the growth of the global acute respiratory distress syndrome (ARDS) market. The key market challenge in the global acute respiratory distress syndrome (ARDS) market is the stringent Regulations for approval and multiple challenges faced by ICU nurses.
Impact of COVID-19 on the Global Acute Respiratory Distress Syndrome Market
The COVID-19 outbreak has had a great impact on the healthcare and pharmaceutical industries around the globe. This pandemic has had a huge positive impact on the ARDS market. COVID-19 being one of the major risk factors for the development of ARDS has not only increased the cases of ARDS and also the huge investment of time and resources for the development of a cure and vaccine for COVID-19 has led to changes and advancements in therapy and treatment management for ARDS cases. This outbreak has also led to increased awareness among the public related to ARDS further leading to the growth of the market.
Scope of the report
| Report Metric | Details |
| Market size available for years | 2019-2030 |
| Base year considered | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | By Type, By Cause, By Device Type, By Injury, By Route Of Administration, By End-User Industry, By Distribution Channel
|
| Geographies covered | North America, Europe, APAC, Latin America, and the Middle East & Africa |
| Companies Covered | Armstrong Medical, ALung Technologies, Inc., Besmed Health Business Corp., BPL medical technologies, Beurer Gmbh, Drägerwerk AG & Co. KGaA, EUROSETS, Fisher & Paykel Healthcare Limited, Fresenius SE & Co. KGaA, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., Getinge AB, Hamilton Medical, LivaNova PLC, Medtronic, Nice Neotech Medical Systems Pvt. Ltd., NIPRO, Pfizer Inc., Terumo Medical Corporation, WEINMANN Emergency Medical Technology GmbH + Co. KG.
|
Global Acute Respiratory Distress Syndrome Market, By Type:
Based on the Type, Global Acute Respiratory Distress Syndrome Market is segmented as; Diagnosis {Imaging testing (Chest X-RAY, CT- scan, Ultrasound, Others), Blood test, Respiratory, SPO2 test, others}, Treatment {Mechanical ventilation (High-flow nasal O2, BI-level positive airway pressure, Continuous positive airway pressure, Prone positive ventilation, others), Corticosteroids (Methylprednisolone, Dexamethasone, Others), Antiviral medication (Remdesivir, Combination drugs, others), Extracorporeal membrane oxygenation, Tocilizumab, Others}.
Global Acute Respiratory Distress Syndrome Market, By Cause:
Based on the Cause, Global Acute Respiratory Distress Syndrome Market is segmented as; Coronavirus disease 2019 (COVID-19), Sepsis, Inhalation of harmful substances, Severe pneumonia, others.
Global Acute Respiratory Distress Syndrome Market, By Device Type:
Based on the Device Type, Global Acute Respiratory Distress Syndrome Market is segmented as; Monitoring devices (Key market trends, growth factors and opportunities, Market size and forecast, Market share analysis), Diagnostic devices (Key market trends, growth factors and opportunities, Market size and forecast, Market share analysis), Therapeutic devices (Key market trends, growth factors and opportunities, Market size and forecast, Market share analysis).
Global Acute Respiratory Distress Syndrome Market, By Injury:
Based on the Injury, Global Acute Respiratory Distress Syndrome Market is segmented as; Brain (Key market trends, growth factors and opportunities, Market size and forecast, Market share analysis), Lungs (Key market trends, growth factors and opportunities, Market size and forecast, Market share analysis).
Global Acute Respiratory Distress Syndrome Market, By Route Of Administration:
Based on the ROA, Global Acute Respiratory Distress Syndrome Market is segmented as; Parenteral (Intravenous, Intramuscular), Oral, Others.
Global Acute Respiratory Distress Syndrome Market, By End-User Industry:
Based on the End-user Industry, Global Acute Respiratory Distress Syndrome Market is segmented as; Hospitals, Specialty clinics, Home healthcare, Others.
Global Acute Respiratory Distress Syndrome Market, By Distribution Channel:
Based on the Distribution Channel, Global Acute Respiratory Distress Syndrome Market is segmented as; Direct tender, Hospital pharmacy, Retail pharmacy, Online pharmacy.
Global Acute Respiratory Distress Syndrome Market, By Region:
Because of the country's increasing technological advancement, the diagnosis segment in the North American region is expected to grow at the fastest rate during the forecast period. Due to an increase in chronic respiratory diseases and widespread adoption of proper diagnosis, Germany's diagnosis segment dominates the European market. Because of the growing number of biotechnology centers and research activities in Japan, the diagnosis segment is dominating the Asia-Pacific market.
1. Introduction
1.1. Scope of the report
1.2. Market segment analysis
2. Research Methodology
2.1 Research data source
2.1.1 Secondary data
2.1.2 Primary data
2.1.3 SPER’s internal database
2.1.4 Premium insight from KOL’s
2.2 Market size estimation
2.2.1 Top-down and Bottom-up approach
2.3 Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2. COVID-19 Impacts of the Global Acute Respiratory Distress Syndrome Market
5. Market variables and outlook
5.1. SWOT analysis
5.1.1 Strengths
5.1.2 Weaknesses
5.1.3 Opportunities
5.1.4 Threats
5.2. PESTEL analysis
5.2.1 Political landscape
5.2.2 Economic landscape
5.2.3 Social landscape
5.2.4 Technological landscape
5.2.5 Environmental landscape
5.2.6 Legal landscape
5.3. PORTER’S five forces analysis
5.3.1 Bargaining power of suppliers
5.3.2 Bargaining power of Buyers
5.3.3 Threat of Substitute
5.3.4 Threat of new entrant
5.3.5 Competitive rivalry
5.4. Heat map analysis
6. Global Acute Respiratory Distress Syndrome Market, By Type, 2019-2030 (USD Million)
6.1. Diagnosis
6.1.1. Imaging testing
6.1.1.1. Chest X-RAY
6.1.1.2. CT- scan
6.1.1.3. Ultrasound
6.1.1.4. Others
6.1.2. Blood test
6.1.3. Respiratory
6.1.4. SPO2 test
6.1.5. Others
6.2. Treatment
6.2.1. Mechanical ventilation
6.2.1.1. High-flow nasal O2
6.2.1.2. BI-level positive airway pressure
6.2.1.3. Continuous positive airway pressure
6.2.1.4. Prone positive ventilation
6.2.1.5. Others
6.2.2. Corticosteroids
6.2.2.1. Methylprednisolone
6.2.2.2. Dexamethasone
6.2.2.3. Others
6.2.3. Antiviral medication
6.2.3.1. Remdesivir
6.2.3.2. Combination drugs
6.2.3.3. Others
6.2.4. Extracorporeal membrane oxygenation (ECMO)
6.2.5. Tocilizumab
6.2.6. Others
7. Global Acute Respiratory Distress Syndrome Market, By Cause, 2019-2030 (USD Million)
7.1. Coronavirus disease 2019 (COVID-19)
7.2. Sepsis
7.3. Inhalation of harmful substances
7.4. Severe pneumonia
7.5. Others
8. Global Acute Respiratory Distress Syndrome Market, By Device Type, 2019-2030 (USD Million)
8.1. Monitoring devices
8.1.1. Key market trends, growth factors and opportunities
8.1.2. Market size and forecast
8.1.3. Market share analysis
8.2. Diagnostic devices
8.2.1. Key market trends, growth factors and opportunities
8.2.2. Market size and forecast
8.2.3. Market share analysis
8.3. Therapeutic devices
8.3.1. Key market trends, growth factors and opportunities
8.3.2. Market size and forecast
8.3.3. Market share analysis
9. Global Acute Respiratory Distress Syndrome Market, By Injury, 2019-2030 (USD Million)
9.1. Brain
9.1.1. Key market trends, growth factors and opportunities
9.1.2. Market size and forecast
9.1.3. Market share analysis
9.2. Lungs
9.2.1. Key market trends, growth factors and opportunities
9.2.2. Market size and forecast
9.2.3. Market share analysis
10. Global Acute Respiratory Distress Syndrome Market, By Route Of Administration, 2019-2030 (USD Million)
10.1. Parenteral
10.1.1. Intravenous
10.1.2. Intramuscular
10.2. Oral
10.3. Others
11. Global Acute Respiratory Distress Syndrome Market, By End-User Industry, 2019-2030 (USD Million)
11.1. Hospitals
11.2. Specialty clinics
11.3. Home healthcare
11.4. Others
12. Global Acute Respiratory Distress Syndrome Market, By Distribution Channel, 2019-2030 (USD Million)
12.1. Direct tender
12.2. Hospital pharmacy
12.3. Retail pharmacy
12.4. Online pharmacy
13. Global Acute Respiratory Distress Syndrome Market, By Region, 2019-2030 (USD Million)
13.1. North America
13.1.1. United States
13.1.2. Canada
13.1.3. Mexico
13.2. Europe
13.2.1. Germany
13.2.2. United Kingdom
13.2.3. France
13.2.4. Italy
13.2.5. Spain
13.2.6. Rest of Europe
13.3. Asia-Pacific
13.3.1. China
13.3.2. Japan
13.3.3. India
13.3.4. Australia
13.3.5. South Korea
13.3.6. Rest of Asia-Pacific
13.4. South America
13.4.1. Brazil
13.4.2. Argentina
13.4.3. Rest of South America
13.5. Middle East & Africa
13.5.1. Kingdom of Saudi Arabia
13.5.2. United Arab Emirates
13.5.3. Rest of Middle East & Africa
14. Company Profiles
14.1. Armstrong Medical
14.1.1. Company details
14.1.2. Financial outlook
14.1.3. Product summary
14.1.4. Recent developments
14.2. ALung Technologies, Inc.
14.2.1. Company details
14.2.2. Financial outlook
14.2.3. Product summary
14.2.4. Recent developments
14.3. Besmed Health Business Corp.
14.3.1. Company details
14.3.2. Financial outlook
14.3.3. Product summary
14.3.4. Recent developments
14.4 BPL medical technologies
14.4.1. Company details
14.4.2. Financial outlook
14.4.3. Product summary
14.4.4. Recent developments
14.5. Beurer Gmbh
14.5.1. Company details
14.5.2. Financial outlook
14.5.3. Product summary
14.5.4 Recent developments
14.6. Drägerwerk AG & Co. KGaA
14.6.1. Company details
14.6.2. Financial outlook
14.6.3. Product summary
14.6.4. Recent developments
14.7. EUROSETS
14.7.1. Company details
14.7.2. Financial outlook
14.7.3. Product summary
14.7.4. Recent developments
14.8. Fisher & Paykel Healthcare Limited
14.8.1. Company details
14.8.2. Financial outlook
14.8.3. Product summary
14.8.4. Recent developments
14.9. Fresenius SE & Co. KGaA
14.9.1. Company details
14.9.2. Financial outlook
14.9.3. Product summary
14.9.4. Recent developments
14.10. F. Hoffmann-La Roche Ltd
14.10.1. Company details
14.10.2. Financial outlook
14.10.3. Product summary
14.10.4. Recent developments
14.11 Gilead Sciences, Inc.
14.11.1. Company details
14.11.2. Financial outlook
14.11.3. Product summary
14.11.4. Recent developments
14.12. Getinge AB
14.12.1. Company details
14.12.2. Financial outlook
14.12.3. Product summary
14.12.4. Recent developments
14.13. Hamilton Medical
14.13.1. Company details
14.13.2. Financial outlook
14.13.3. Product summary
14.13.4. Recent developments
14.14. LivaNova PLC
14.14.1. Company detail
14.14.2. Financial outlook
14.14.3. Product summary
14.14.4. Recent developments
14.15. Medtronic
14.15.1. Company details
14.15.2. Financial outlook
14.15.3. Product summary
14.15.4. Recent developments
14.16. Nice Neotech Medical Systems Pvt. Ltd.
14.16.1. Company details
14.16.2. Financial outlook
14.16.3. Product summary
14.16.4. Recent development
14.17. NIPRO
14.17.1. Company details
14.17.2. Financial outlook
14.17.3. Product summary
14.17.4. Recent development
14.18. Pfizer Inc.
14.18.1. Company details
14.18.2. Financial outlook
14.18.3. Product summary
14.18.4. Recent development
14.19. Terumo Medical Corporation
14.19.1. Company details
14.19.2. Financial outlook
14.19.3. Product summary
14.19.4. Recent development
14.20. WEINMANN Emergency Medical Technology GmbH + Co. KG
14.20.1. Company details
14.20.2. Financial outlook
14.20.3. Product summary
14.20.4. Recent development